

# Quarterly Report Q2 2023 All data ranges cut off at the end of Q2 (6/30/2023) All annualizations based on 1/1/2023 - 6/30/2023

#### **Table of Contents**

Actual Wait Times to Transplant Compatible Pairs who Received a Low Eplet Mismatch Transplant	Kidney for Life Results One Year Antibody Screening
	Living Donors Supported and Protected By Donor Type
Death Censored Graft Failure Comparisons	Living Kidney Donations Resulting from NKR Donor Referrals 2
Decoupling Trend Transition from Paired to Standard Voucher Donation	Low Eplet Mismatch Transplants Percentage of Voucher & Paired Recipients Receiving a Low Eplet Mismatch Transplant
Dialysis Patients Waiting More Than One Year Due to High cPRA 42	Median Wait Time by Blood Type From Exportability to Transplant 4
Donor Registration Type Kidney Registrations Across All DASH Intake Platforms	Median Wait Time to Transplant From Exportability to Transplant 4
Donor Shield Reimbursements The NKR is Reimbursing over	Message from the Founder & CEO
\$5M Annually to Eliminate Disincentives	Microsite Centers
Good Samaritan Donor Candidate Registrations Kidney Registrations Across All DASH Intake Platforms	Microsite Donor Registrations
Higher Conversion Rates with Donor Connect Private Label DASH Donations / Average Registrations 29	Microsite Enrollment Success Percentage of Waitlist Patients with Microsites
Home Blood Draw Requests	Microsite Growth
Kidney for Life Centers	Microsite Patient Referrals
Kidney for Life Low Eplet Mismatch Transplants Compatible and	Microsite Patients Receiving Living Donor Transplants
Incompatible Pairs	New Exportable Patients Paired and Standard Voucher
Kidney for Life Low Eplet Mismatch Transplants Compatible and Incompatible Pairs 7/1/2022 – 6/30/2023	NKR Donor Conversion Rates Donations Divided by Average Referrals.
Kidney for Life Low Eplet Mismatch Transplants Compatible Pairs 7/1/2022 – 6/30/2023	NKR Facilitated Transplant Growth
Kidney for Life Patient Referrals 30	NKR Kidney Donor Referrals Completed Online Screening, Medical History and Labs

20	Pool Composition by cPRA Unmatched Paired and Voucher Patients 37
31	Remote Donations by Donor Type
27	Resources
04	Swap Failure Rates
21	Swaps Saved by Swap Saver Voucher Donors
41	Top 10 Centers in the U.S.2022 Living Donor Kidney Transplants 6
40	Top 10 Centers in the U.S.2022 Living Donor KPD Kidney Transplants 7
. 3	Top 10 Centers Most Active Microsites
14	Top 10 Centers NKR Facilitated Transplants – Last 12 months 5
12	Total Eplet Mismatch Transplants by Type All Patient Types 18
10	Transition to Family Voucher Donation
8	Transplanted Recipients by cPRA
13	Wait Time Distribution – Incompatible Pairs Exportability to Transplant – Paired & Voucher Wait Times



#### Message from the Founder & CEO



The National Kidney Registry facilitated 675 transplants in the first half of this year, up 21% over the 560 transplants facilitated in the first half of 2022. The growth in NKR-facilitated transplants was primarily driven by increases in microsite patient transplants, strong growth in NKR donor candidates referred to Member Centers and an increase in compatible pairs seeking low eplet mismatched donors through our Kidney for Life platform.

During Q2, the NKR helped to launch ImmunoFree Inc., a newly formed biotech company whose mission is to eliminate the need for lifelong immunosuppressive medications for transplant recipients, thus enabling them to live longer, healthier lives. ImmunoFree purchased the transplant tolerance business of Talaris Therapeutics in July and will commence a new clinical trial in the next 6–12 months following FDA-approved modifications to the protocol. The new protocol will include an improved conditioning regimen, a focus on delayed tolerance and better donor-recipient genetic matching achieved by leveraging the NKR's Kidney for Life Expert System. These protocol changes are designed to reduce the risk of graft versus host disease and maximize the number of transplant recipients that can be weaned off immunosuppressive medications.


ImmunoFree intends to lead with delayed tolerance, a protocol that allows patients to recover from their kidney transplant for several months prior to undergoing the associated conditioning protocol and tolerance-inducing stem-cell transplant. The clinical trial data indicate that the genetic match between the donor and recipient is critical, so the initial trial enrollment criteria will likely limit enrollment to patients who have received a low eplet mismatch transplant in the past 5 years and have a bone marrow transplant (BMT) HLA mismatch of 0–4 (allele level matching on A, B, C and DR). We will implement the BMT HLA mismatch information in the KFL Expert System within the next 30 days so that centers can give their patients the best opportunity to participate in the ImmunoFree delayed tolerance program in the future.

Sincerely,

Garet Hil

Founder & CEO
National Kidney Registry
Living Kidney Donor

#### **NKR Facilitated Transplant Growth**



Annualized


<sup>\*\*</sup>https://optn.transplant.hrsa.gov/data/ U.S. Living Donor (LD) Transplants Performed: Data for OPTN 1/1/2008 – 6/18/2023.



<sup>\*</sup>NKR facilitated transplants (TXPs) include voucher, paired, remote directs, KFL remote directs, NKR internal direct, microsite internal direct, and WLP transplants. Total transplants subject to change due to delayed reporting. NKR data captured 6/30/2023.

# **Top 10 Centers**

NKR Facilitated Transplants – Last 12 months




NKR facilitated transplants include voucher, paired, remote directs, Kidney for Life remote directs, NKR internal direct, microsite direct transplants, and waitlist patient transplants. As of 7/1/2023.



#### Top 10 Centers in the U.S.

2022 Living Donor Kidney Transplants




2022 UNOS Data.



#### Top 10 Centers in the U.S.


2022 Living Donor KPD Kidney Transplants



2022 UNOS Data.




#### **Microsite Growth**





## Microsite Patients Receiving Living Donor Transplants




As of 7/1/2023. 2023 under-reported due to delay in TXP Centers reporting.



#### **Microsite Enrollment Success**

Percentage of Waitlist Patients with Microsites




NKR Microsite Date for 7/1/2023. Latest OPTN Waitlist data for 3/2023. Formula: Active Microsites / Total Waitlist. Minimum 10%



# **Top 10 Centers**


#### Most Active Microsites



Kidney only. As of 7/1/2023.




# **Microsite Donor Registrations**








#### **Microsite Patient Referrals**





#### **Microsite Centers**




As of 8/3/2023.

To see the latest microsite participating centers click here.



## **Kidney for Life Low Eplet Mismatch Transplants**

Compatible and Incompatible Pairs




Excludes waitlist and remote direct. As of 7/1/2023.

Eplet mismatch categories are based on the definition provided by Wiebe C, Kosmoliaptsis V, Pochinco D, et al. HLA-DR/DQ molecular mismatch: a prognostic biomarker for primary alloimmunity. Am J Transplant. 2019;19:1708–1719. https://doi.org/10.1111/ajt.15177



#### **Kidney for Life Low Eplet Mismatch Transplants**

Compatible and Incompatible Pairs 7/1/2022 – 6/30/2023



Excludes waitlist and remote direct. As of 7/1/2023. Minimum 2 Transplants.


Eplet mismatch categories are based on the definition provided by Wiebe C, Kosmoliaptsis V, Pochinco D, et al. HLA-DR/DQ molecular mismatch: a prognostic biomarker for primary alloimmunity.

Am J Transplant. 2019;19:1708–1719. https://doi.org/10.1111/ajt.15177



## **Kidney for Life Low Eplet Mismatch Transplants**

Compatible Pairs 7/1/2022 - 6/30/2023




Excludes waitlist and remote direct. Minimum 2 transplants. As of 7/1/2023.

Eplet mismatch categories are based on the definition provided by Wiebe C, Kosmoliaptsis V, Pochinco D, et al. HLA-DR/DQ molecular mismatch: a prognostic biomarker for primary alloimmunity. Am J Transplant. 2019;19:1708–1719. <a href="https://doi.org/10.1111/ajt.15177">https://doi.org/10.1111/ajt.15177</a>



## **Total Eplet Mismatch Transplants by Type**




As of 7/1/2023.

Eplet mismatch categories are based on the definition provided by Wiebe C, Kosmoliaptsis V, Pochinco D, et al. HLA-DR/DQ molecular mismatch: a prognostic biomarker for primary alloimmunity. Am J Transplant. 2019;19:1708–1719. https://doi.org/10.1111/ait.15177



#### **Actual Wait Times to Transplant**

Compatible Pairs who Received a Low Eplet Mismatch Transplant




Data for 7/1/2022 – 6/30/2023. cPRA ≤ 99.



#### **Kidney for Life Results**

One Year Antibody Screening




De Novo DSA is defined by MFI > 1000 but may not be clinically significant. Data for last 12 months as of 7/1/2023.



#### **Low Eplet Mismatch Transplants**

Percentage of Voucher & Paired Recipients Receiving a Low Eplet Mismatch Transplant


Medium/High or No TypingLow/Zero Eplet Mismatch



Excludes non-KPD and waitlist patient transplants. As of 7/1/2023.



#### **Death Censored Graft Failure Comparisons**




<sup>\*</sup>Statistically significant

Provided courtesy of NYU Grossman School of Medicine, Department of Surgery \*Not including waitlist patients; Kaplan-Meier GS Rates for Transplants Performed: 02/2008-12/2021 with follow-up through 3/31/2022. <a href="https://www.str.org/SRTR">https://www.str.org/SRTR</a> data as of June 2022.



#### **Kidney for Life Centers**




As of 8/3/2023.

To see the latest Kidney for Life participating centers <u>click here</u>.



#### **Donor Registration Type**


Kidney Registrations Across All DASH Intake Platforms





## **Good Samaritan Donor Candidate Registrations**


Kidney Registrations Across All DASH Intake Platforms





#### **NKR Kidney Donor Referrals**

Completed Online Screening, Medical History and Labs




As of 7/1/2023. Includes donor registrants from all NKR websites.



# **Living Kidney Donations**

Resulting from NKR Donor Referrals




As of 7/1/2023.

To avoid lag-effect, the chart counts donation date which does not reflect the date the donor registered.



#### **NKR Donor Conversion Rates**

#### Donations Divided by Average Referrals



As of 7/1/2023.


Formula: Donations / Average Referrals

Average Referrals: (Annualized Current Year Referrals + Prior Year Referrals) / 2



# **Higher Conversion Rates with Donor Connect**

Private Label DASH Donations / Average Registrations




	Mentor Declined	Mentor Accepted
2023 Donations (Annualized)	124	554
2023 Registrations (Annualized)	11,720	18,398
2022 Registrations	7,863	11,618
Average Registrations	9,792	15,008
Registration to Donation Rate	1.3%	3.7%

Data for all private-label DASH registrants across all centers who were offered a mentor during registration (43% in 2022). 1/1/2023 – 6/30/2023.



# **Kidney for Life Patient Referrals**









## **Living Donors Supported and Protected**

#### By Donor Type








#### **Donor Shield Reimbursements**

The NKR is Reimbursing over \$5M Annually to Eliminate Disincentives




As of 7/1/2023.

Primary costs related to lost wage and travel/lodging reimbursements.

Learn more at <a href="https://www.donor-shield.org">www.donor-shield.org</a>




## **Remote Donations by Donor Type**






#### **Home Blood Draw Requests**








# **Transition to Family Voucher Donation**





## **Decoupling Trend**


Transition from Paired to Standard Voucher Donation





## **Pool Composition by cPRA**


**Unmatched Paired and Voucher Patients** 





#### **New Exportable Patients**

Paired and Standard Voucher




Data for paired and standard voucher patients only. As of 7/1/2023.



#### **Wait Time Distribution – Incompatible Pairs**

Exportability to Transplant – Paired & Voucher Wait Times




All cPRA groups. As of 7/1/2023.



# **Median Wait Time to Transplant**

From Exportability to Transplant




Total wait time including paired and voucher. Excludes non-KPD and waitlist patient transplants. As of 7/1/2023.



#### **Median Wait Time by Blood Type**

From Exportability to Transplant



Total wait time including paired and voucher. Excludes non-KPD and waitlist patient transplants. As of 7/1/2023.



## **Dialysis Patients Waiting More Than One Year**

Due to High cPRA

#### **Paired Patients**

#	Patient ID	Patient ABO	cPRA	Months Wait
	AULUM LULE			
1	5501	В	100.00	90
2	12411	Α	100.00	33
3	10569	Α	100.00	24
4	10275	В	100.00	21
5	14941	0	100.00	19
6	15355	0	100.00	17
7	15347	Α	100.00	17
8	15219	В	100.00	17
9	15582	0	100.00	14
10	10986	0	99.99	41
11	16200	0	99.99	13
12	12565	0	99.98	26
13	15238	0	99.97	17
14	15282	0	99.96	17
15	13846	А	99.90	20
16	12531	0	99.74	25
17	14093	0	99.52	22
18	15904	0	99.33	15


#### **Voucher Patients**

#	Patient ID	Patient ABO	cPRA	Months Wait
1	13055	0	100.00	30
2	10069	Α	99.99	45
3	12712	В	99.97	24
4	16062	0	99.84	13
5	14307	0	99.49	12

As of 7/1/2023. Includes all patients on dialysis & exportable in the NKR pool with a cPRA >99.00.




#### **Transplanted Recipients by cPRA**



As of 7/1/2023.
Excludes all non-KPD and waitlist patient transplants.




## **Swap Failure Rates**



YTD




# **Swaps Saved by Swap Saver Voucher Donors**






#### Resources









kidneyregistry.org


donor-shield.org

kidneytransplantcenters.org

donorcarenet.org







kidneyforlife.org

findakidney.org

livingdonorgames.org

